Latest & greatest articles for prednisolone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisolone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisolone

1. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) Full Text available with Trip Pro

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Jan 20;39(3):190-201. doi: 10.1200/JCO.20.01576. Epub 2020 Dec 16. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone

2021 EvidenceUpdates

2. Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study)

Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study) Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) ) Actions . 2020 Nov 7;keaa685. doi: 10.1093/rheumatology/keaa685. Online ahead of print. Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study) , , , , , , , Affiliations Expand Affiliations 1 Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2 Department of Orthopedics, Postgraduate Institute

2020 EvidenceUpdates

3. Submucosal administration of dexamethasone versus methyl prednisolone in management of postoperative sequelae after mandibular third molar impaction - A systematic review Full Text available with Trip Pro

Submucosal administration of dexamethasone versus methyl prednisolone in management of postoperative sequelae after mandibular third molar impaction - A systematic review Submucosal administration of dexamethasone versus methyl prednisolone in management of postoperative sequelae after mandibular third molar impaction - A systematic review | International Journal of Research in Pharmaceutical Sciences Quick jump to page content Toggle navigation Review Articles Section Review Articles (...) Submucosal administration of dexamethasone versus methyl prednisolone in management of postoperative sequelae after mandibular third molar impaction - A systematic review Janani Kandamani jananikandamani@gmail.com (Primary Contact) Department of Oral and Maxillofacial Surgery, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, No 162, PoonamalleeHigh Road, Vellappanchavadi, Chennai-600077, Tamil Nadu, India Divya Sanjeevi Ramakrishnan

2020 International Journal of Research in Pharmaceutical Sciences

4. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. (Abstract)

Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Hand osteoarthritis is a prevalent joint condition that has a high burden of disease and an unmet medical need for effective therapeutic options. Since local inflammation is recognised as contributing to osteoarthritic complaints, the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study aimed to investigate the efficacy and safety of short (...) -term prednisolone in patients with painful hand osteoarthritis and synovial inflammation.The HOPE study is a double-blind, randomised, placebo-controlled trial. We recruited eligible adults from rheumatology outpatient clinics at two sites in the Netherlands. Patients were considered eligible if they had symptomatic hand osteoarthritis and signs of inflammation in their distal and proximal interphalangeal (DIP/PIP) joints. For inclusion, patients were required to have four or more DIP/PIP joints

2019 Lancet

5. Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Full Text available with Trip Pro

Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial The use of either prednisolone or low-dose dexamethasone in the treatment of childhood croup lacks a rigorous evidence base despite widespread use. In this study, we compare dexamethasone at 0.6 mg/kg with both low-dose dexamethasone at 0.15 mg/kg and prednisolone at 1 mg/kg.Prospective, double-blind, noninferiority randomized controlled trial based in 1 tertiary pediatric emergency department and 1 urban district (...) emergency department in Perth, Western Australia. Inclusions were age >6 months, maximum weight 20 kg, contactable by telephone, and English-speaking caregivers. Exclusion criteria were known prednisolone or dexamethasone allergy, immunosuppressive disease or treatment, steroid therapy or enrollment in the study within the previous 14 days, and a high clinical suspicion of an alternative diagnosis. A total of 1252 participants were enrolled and randomly assigned to receive dexamethasone (0.6 mg/kg; n

2019 EvidenceUpdates

6. Wide heterogeneity in treatment protocols and inappropiate use of prednisolone for anti-Ro/La associated-congenital heart block: a systematic review of 492 cases Full Text available with Trip Pro

Wide heterogeneity in treatment protocols and inappropiate use of prednisolone for anti-Ro/La associated-congenital heart block: a systematic review of 492 cases Ulusal Romatoloji Dergisi / ISSN:2651-2653 E-ISSN:2651-2661 / ISSN:2651-2653 E-ISSN:2651-2661 Toggle navigation / Ay: 12 Yıl: 2020 Sayı: 3 Cilt: 12 Orijinal Araştırma Güllü Alakbarova Döndü Üsküdar Cansu Cengiz Korkmaz J Turk Soc Rheumatol 2020; 12: 64-70 DOI: 10.4274/raed.galenos.2020.30074 Duygu Temiz Karadağ Burçin Gönül Özlem

2019 Ulusal Romatoloji Dergisi

7. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. Full Text available with Trip Pro

Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. To determine whether extending initial prednisolone treatment from eight to 16 weeks in children with idiopathic steroid sensitive nephrotic syndrome improves the pattern of disease relapse.Double blind, parallel group, phase III randomised placebo controlled trial, including a cost effectiveness analysis.125 UK National (...) Health Service district general hospitals and tertiary paediatric nephrology centres.237 children aged 1-14 years with a first episode of steroid sensitive nephrotic syndrome.Children were randomised to receive an extended 16 week course of prednisolone (total dose 3150 mg/m2) or a standard eight week course of prednisolone (total dose 2240 mg/m2). The drug was supplied as 5 mg tablets alongside matching placebo so that participants in both groups received the same number of tablets at any time point

2019 BMJ Controlled trial quality: predicted high

8. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (Abstract)

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients (...) with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients.We did a randomised, double-blind, placebo-controlled, phase 3 trial at 165 oncology and urology centres in 19 countries. Eligible patients were aged 18 years or older, and had histologically confirmed, progressive, chemotherapy-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer and bone metastases

2019 EvidenceUpdates

9. HYDROCORTANCYL (prednisolone), glucocorticoid

HYDROCORTANCYL (prednisolone), glucocorticoid Haute Autorité de Santé - HYDROCORTANCYL (prednisolone), glucocorticoïde Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments HYDROCORTANCYL (prednisolone), glucocorticoïde Substance active (DCI) prednisolone RHUMATOLOGIE - Mise au point Nature de la demande Réévaluation SMR Avis de la CT du 09

2018 Haute Autorite de sante

10. Prednisolone

Prednisolone Top results for prednisolone - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prednisolone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

11. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma (Abstract)

A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma Whether itraconazole monotherapy is effective in the acute stage of allergic bronchopulmonary aspergillosis (ABPA) remains unknown. The goal of this study was to compare the efficacy and safety of itraconazole and prednisolone monotherapy in ABPA.Treatment-naive subjects with ABPA complicating asthma (January 2012 to December 2013) were randomized to receive either oral (...) itraconazole or prednisolone for 4 months. The study was not blinded. The primary outcomes were proportion of subjects exhibiting a composite response after 6 weeks, percent decline in IgE after treatment, and numbers of subjects experiencing exacerbation. The secondary outcomes included the time to first exacerbation, change in lung function, and treatment-related adverse effects.A total of 131 subjects (prednisolone group, n = 63; itraconazole group, n = 68) were included in the study. The number

2018 EvidenceUpdates

12. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone | European Medicines Agency Search Search Menu Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Ongoing clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating (...) the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA's ( ) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate cancer patients. In this study 34.7% of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so far, compared with 28.2% of patients given placebo, Zytiga and prednisone

2018 European Medicines Agency - EPARs

13. Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures

Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures - GOV.UK GOV.UK uses cookies to make the site simpler. Search Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone (...) and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures A European review has begun into the safety of radium-223 dichloride following an observed increase in the incidence of deaths and fractures in patients with chemotherapy-naive metastatic castration-resistant prostate cancer receiving radium-223 dichloride in combination with abiraterone acetate (Zytiga) and prednisone/prednisolone as part of a clinical trial. Until full analysis of the results is completed

2017 MHRA Drug Safety Update

14. Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial. Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence.To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma.Multicenter, placebo-controlled (...) , randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices in England among 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disease or use of asthma medication in the past 5 years.Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once daily for 5 days.The primary outcomes were duration of moderately bad or worse cough (0 to 28 days

2017 JAMA Controlled trial quality: predicted high

15. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Full Text available with Trip Pro

Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Oral glucocorticoid treatment increases fracture risk, and evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids.To investigate whether alendronate treatment in older patients using oral prednisolone is associated with decreased hip fracture risk and adverse effects.Retrospective cohort study using a national database (N (...)  = 433 195) of patients aged 65 years or older undergoing a health evaluation (baseline) at Swedish health care facilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment (≥5 mg/d) were identified. Propensity score matching was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone with the same dose and treatment time criteria. Follow-up occurred between January 2008 and December 2014.Alendronate vs no alendronate

2017 JAMA

16. AB0471 Wide heterogeneity in treatment protocols and inappropiate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases Full Text available with Trip Pro

AB0471 Wide heterogeneity in treatment protocols and inappropiate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases AB0471 Wide heterogeneity in treatment protocols and inappropiate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases | Annals of the Rheumatic Diseases Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here AB0471 Wide heterogeneity in treatment protocols and inappropiate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases Article Text Abstracts Accepted for Publication SLE, Sjögren's and APS - clinical aspects

2017 Abstracts Accepted for Publication

17. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA Full Text available with Trip Pro

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA Infections are common in patients with severe alcoholic hepatitis (SAH), but little information is available on how to predict their development or their effects on patients. Prednisolone is advocated for treatment of SAH, but can increase susceptibility to infection. We compared the effects of infection (...) on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH.We analyzed data from 1092 patients enrolled in a double-blind placebo-controlled trial to evaluate the efficacy of treatment with prednisolone (40 mg daily) or pentoxifylline (400 mg 3 times each day) in patients with SAH. The 2 × 2 factorial design led to 547 patients receiving prednisolone; 546 were treated with pentoxifylline. The trial was conducted in the United

2017 EvidenceUpdates

18. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Full Text available with Trip Pro

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.We did a pragmatic, multicentre, parallel-group randomised controlled (...) trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3

2017 Lancet Controlled trial quality: predicted high

19. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Full Text available with Trip Pro

Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Two recent double-blind, randomized, controlled trials (RCTs) showed that oral steroids and nonsteroidal anti-inflammatory drugs have similar analgesic effectiveness for management of gout, but the trials had small sample sizes and other methodological limitations.To compare the effectiveness and safety of oral prednisolone versus oral indomethacin in patients presenting to emergency (...) departments (EDs) with acute gout.Multicenter, double-blind, randomized equivalence trial. Patients were randomly assigned (1:1 ratio) to receive either indomethacin or prednisolone. (ISRCTN registry number: ISRCTN45724113).Four EDs in Hong Kong.416 patients aged 18 years or older.Analgesic effectiveness was defined as changes in pain (at rest or with activity) greater than 13 mm on a 100-mm visual analogue scale. Outcomes were measured during the first 2 hours in the ED and from days 1 to 14.376 patients

2016 Annals of Internal Medicine Controlled trial quality: predicted high

20. In children under 7 years of age does the administration of Dexamethasone result in better outcomes for Croup than the administration of Prednisolone?

In children under 7 years of age does the administration of Dexamethasone result in better outcomes for Croup than the administration of Prednisolone? Getting Evidence into Clinical Practice: General Practice Nurse Evidence Based Practice (CAT Group) Date: July 2016 CAT Lead: Vicky Shone and John Edwards Date CAT completed: July 2016 Email:a.finney@keele.ac.uk Date CAT to be reviewed: July 2018 Specific Question: In children under 7 years of age does the administration of Dexamethasone result (...) in better outcomes for Croup than the administration of Prednisolone? Clinical bottom line Dexamethasone is not statistically or clinically superior to Prednisolone in reducing Croup symptom scores at 6 hours after admission but is superior to Prednisolone at reducing the risk of re-consultation for the same episode of Croup. Dependent on consultation patterns, and whether multiple doses can be used from the same bottle of Dexamethasone, there may also be cost savings associated with a switch

2016 Home Modification Information Clearinghouse